We recently compiled a list of the 10 Best Multibagger Penny Stocks of 2025. In this article, we are going to take a look at where AbCellera Biologics Inc. (NASDAQ:ABCL) stands against the other multibagger penny stocks.
What Are Multibagger Stocks And How To Identify Them
The term “multibagger” was coined by Peter Lynch in his book titled “One Up On Wall Street” to describe those stocks whose share prices increase several times more than an investor’s original investment. Typically, a multibagger stock is one that can be expected to rise by 100% or more – a huge number that warrants the immense attention investors are giving to multibagger stocks today. Lynch himself is an American investor who managed the Magellan Fund at Fidelity Investments from 1977 to 1990. On multibagger stocks, Lynch noted in his book that these are typically fast-growing companies with the potential to yield significant returns over time. He thus considers investment portfolios that own a diverse variety of numerous stocks to be better placed to benefit from multibagger stocks and their growth, in stark contrast to those portfolios that are overly concentrated on investing in a few companies.
When aiming to invest in multibagger stocks, many investors may wonder about where they can begin to look for these miracle-growth companies. The first few things to consider when looking for such stocks include a company’s fundamentals, ability to act as a pioneer in its industry, and the size of the market it operates in. Generally, a multibagger stock is one that has solid financials, such as robust revenue growth and rising profits, and one that is driving innovation in its industry. Additionally, smaller innovative companies operating in a large addressable market also have the potential to be multibaggers in their fields. This is why many multibaggers are actually penny stocks that are just beginning to generate profits and returns for their investors.
Is The Market Favorable For Penny Stocks?
A lot of investors may feel skeptical when it comes to investing in penny stocks or any small or microcap company – for good reason. These stocks are incredibly volatile and make for very risky investments, seeing as their business is just starting out, and there’s really not much to go on with respect to past fundamentals. However, risky investments often end up being highly rewarding, which is why investors who have a greater tolerance for risk in their portfolios generally tend to take a leap with penny stocks.
The market at present also seems to be gearing up to prove beneficial for the overall growth of penny stocks and small-cap companies. According to Chris Retzler, Needham Small Cap Growth Fund’s portfolio manager, while smaller companies are known to be volatile, the long-term outlook for these companies is presently positive. He believes that in the second half of 2024, we may see a broadening of the market, which is generally good for the economy and particularly good for smaller companies that have been underperforming recently.
According to Retzler, one of the main reasons for the growth potential of smaller companies is that they’re incredibly liquid. This factor, coupled with the fact that we are set to see money starting to flow out of bigger companies only to be redirected to smaller companies, means that many small companies and penny stocks may begin to see their share prices rise exponentially. Additionally, the general market expectation to have lower interest rates over the next 12 months is also favorable for penny stocks that don’t really need a lot of money to flow into them before they begin to see higher stock prices and multiple expansion. Will all these developments, many investors are itching to get their hands on multibagger penny stocks, which is why we’ve compiled the following list.
Our Methodology
We used a stock screener to identify stocks trading under $5 with an upside potential of 100% and above to compile our list. The stocks are ranked based on their upside potential as of August 29, from the lowest to the highest. The price targets are analysts’ average estimates for where the stock could be in the next 12 months. We have also mentioned the share prices and number of hedge funds holding a stake in each stock by using Insider Monkey’s hedge fund data for the second quarter.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points. (see more details here).
A research team analyzing data on a computer screen, uncovering details about the antibody discovery platform.
AbCellera Biologics Inc. (NASDAQ:ABCL)
Share Price as of August 29: $2.5
Average Upside Potential as of August 29: 329.7%
Number of Hedge Fund Holders: 16
AbCellera Biologics Inc. (NASDAQ:ABCL) is a healthcare company based in Vancouver, Canada. The company builds an engine for antibody drug discovery and development which discovers antibodies from natural immune responses.
The main reason to buy AbCellera Biologics Inc. (NASDAQ:ABCL) right now is that it has been developing its business rigorously enough to initiate 90 programs with downstream revenue potential by this March. Analysts covering the stock believe its revenue can rise significantly over the coming years. The company is also incredibly liquid. In its second-quarter earnings call, it was noted that AbCellera Biologics Inc. (NASDAQ:ABCL) still has about $700 million in cash and equivalents and approximately $220 million in available government funding to help it execute its programs and operations.
One thing to worry about, though, is AbCellera Biologics Inc.’s (NASDAQ:ABCL) cash burn. In the second quarter, the company’s revenue was $7 million, while its R&D expenses for the quarter were $41 million. Some investors may see this as a cause for concern, but seeing as the company overall ended the quarter with $698 million in cash, equivalents, and marketable security, there does seem to be room for AbCellera Biologics Inc. (NASDAQ:ABCL) to continue its current pace of cash burn for a few more years before it needs to raise more capital. All in all, this biotech penny stock is definitely a risky play, but judging by its upside potential, it may be worth the risk.
There were 16 hedge funds long AbCellera Biologics Inc. (NASDAQ:ABCL) in the second quarter, with a total stake value of $122.2 million.
Overall ABCL ranks 2nd on our list of the best multibagger penny stocks of 2025. While we acknowledge the potential of ABCL as an investment, we believe that AI stocks hold promise for delivering high returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than ABCL but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: $30 Trillion Opportunity: 15 Best Humanoid Robot Stocks to Buy According to Morgan Stanley and Jim Cramer Says NVIDIA ‘Has Become A Wasteland’.
Disclosure: None. This article is originally published at Insider Monkey.
Read More: The Best Multibagger Penny Stock of 2025?